Biomedicine is medicine prepared based on the application of functions and information of organisms, and has been produced by using systems of culturing cells such as enzymes, bacteria and animal cells. However, such cell culture systems have some problems about costs and mass-production, and thus s...
Biomedicine is medicine prepared based on the application of functions and information of organisms, and has been produced by using systems of culturing cells such as enzymes, bacteria and animal cells. However, such cell culture systems have some problems about costs and mass-production, and thus studies and suggestions of effective cell culture systems have been required. In this study, it was conducted to compare kinds of production systems of biomedicine and analyze strengths and weaknesses, and as a result, a biomedicine production system using transgenic animals was selected as the most economical and effective system. The production system, which compensates the weaknesses of microorganisms and animal cells, produces medicines using animals and plants, and has strengths of high stability and cost-effectiveness. In addition, the market of the medicines prepared by using transgenic animals and plants showed a growth rate of 161% in 2008, and is expected to continuously grow until 2020. This study selected patent applications filed in the United States, Japan, Korea and Europe in relation to biomedicine production systems using transgenic animals through KIPRIS and WIPS, and a total of 370 patent applications were selected. 370 patent applications were quantitatively and qualitatively analyzed to see a patent trend. The analysis was quantitatively conducted by year and countries, and qualitatively conducted by technologies, proteins and animals. The result of the quantitative analysis showed that the number of the applications rose after 1990, but decreased after 2006, and that the United States and Europe filed the patent applications the most. In addition, the result of the qualitative analysis showed that a targeting vector technology was developed most actively, studies of proteins such as CI inhibitor, antithrombin III, immune globulin, EPO, insulin, and collagen were conducted, and that all of the applicants (companies or organizations) selected in this study used rats as a transgenic animal, and rabbits, goats, sheep, pigs, and cattle were also used as transgenic animals.
Biomedicine is medicine prepared based on the application of functions and information of organisms, and has been produced by using systems of culturing cells such as enzymes, bacteria and animal cells. However, such cell culture systems have some problems about costs and mass-production, and thus studies and suggestions of effective cell culture systems have been required. In this study, it was conducted to compare kinds of production systems of biomedicine and analyze strengths and weaknesses, and as a result, a biomedicine production system using transgenic animals was selected as the most economical and effective system. The production system, which compensates the weaknesses of microorganisms and animal cells, produces medicines using animals and plants, and has strengths of high stability and cost-effectiveness. In addition, the market of the medicines prepared by using transgenic animals and plants showed a growth rate of 161% in 2008, and is expected to continuously grow until 2020. This study selected patent applications filed in the United States, Japan, Korea and Europe in relation to biomedicine production systems using transgenic animals through KIPRIS and WIPS, and a total of 370 patent applications were selected. 370 patent applications were quantitatively and qualitatively analyzed to see a patent trend. The analysis was quantitatively conducted by year and countries, and qualitatively conducted by technologies, proteins and animals. The result of the quantitative analysis showed that the number of the applications rose after 1990, but decreased after 2006, and that the United States and Europe filed the patent applications the most. In addition, the result of the qualitative analysis showed that a targeting vector technology was developed most actively, studies of proteins such as CI inhibitor, antithrombin III, immune globulin, EPO, insulin, and collagen were conducted, and that all of the applicants (companies or organizations) selected in this study used rats as a transgenic animal, and rabbits, goats, sheep, pigs, and cattle were also used as transgenic animals.
주제어
#바이오의약품 형질전환동물 특허동향
※ AI-Helper는 부적절한 답변을 할 수 있습니다.